Integra LifeSciences Holdings Co. (NASDAQ:IART – Get Free Report) has been given an average recommendation of “Reduce” by the nine research firms that are currently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $26.50.
Several brokerages recently weighed in on IART. Morgan Stanley raised their price target on shares of Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a research report on Monday, July 15th. Bank of America dropped their price target on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a research report on Monday, October 7th. JMP Securities dropped their price target on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating on the stock in a research report on Tuesday, July 30th. Citigroup dropped their price target on shares of Integra LifeSciences from $20.00 to $16.00 and set a “sell” rating on the stock in a research report on Tuesday, October 1st. Finally, Truist Financial dropped their price target on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research report on Monday, October 14th.
View Our Latest Analysis on IART
Institutional Investors Weigh In On Integra LifeSciences
Integra LifeSciences Stock Performance
Shares of Integra LifeSciences stock opened at $18.88 on Friday. The company has a market cap of $1.49 billion, a P/E ratio of 37.76, a PEG ratio of 0.62 and a beta of 1.09. The business has a 50-day moving average price of $18.84 and a two-hundred day moving average price of $25.16. The company has a current ratio of 3.39, a quick ratio of 2.10 and a debt-to-equity ratio of 1.17. Integra LifeSciences has a 1-year low of $16.81 and a 1-year high of $45.42.
Integra LifeSciences (NASDAQ:IART – Get Free Report) last released its quarterly earnings data on Monday, July 29th. The life sciences company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.01. The company had revenue of $418.20 million for the quarter, compared to analysts’ expectations of $413.07 million. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The business’s revenue was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.71 EPS. As a group, analysts anticipate that Integra LifeSciences will post 2.45 EPS for the current year.
About Integra LifeSciences
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Featured Articles
- Five stocks we like better than Integra LifeSciences
- Technology Stocks Explained: Here’s What to Know About Tech
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- Where to Find Earnings Call Transcripts
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.